Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) is a clinical-stage biotherapeutics company whose RaniPill capsule aims to turn injectable biologics into oral pills. Five current analyst price targets were reviewed to calculate the central target: H.C. Wainwright at $11, an unnamed firm at $9, Chardan Capital at $6, and Canaccord Genuity and another firm each at $5. The arithmetic mean of these five targets is $7.20, the figure used throughout this article, with a low-to-high range of $5 to $11.
The analyst consensus is effectively a "Strong Buy," yet the spread between the lowest ($5) and highest ($11) target is unusually wide even by biotechnology standards. This disagreement reflects genuine uncertainty about how the market will value a platform company that has not yet demonstrated late-stage clinical success or meaningful commercial revenue. No single target should be treated as likelier than another, and the mean is not a guarantee.
RANI last traded near $0.61, toward the bottom of a 52-week range of roughly $0.57 to $2.63. To reach $7.20, the shares would need to rise by approximately 1,080%, a very large move. The stock has fallen more than 65% over the past year, so the path toward the target would require a fundamental re-rating of the company rather than incremental progress.
That re-rating would likely depend on clinical data, particularly from the Phase 1 program for RT-114, an orally delivered GLP-1/GLP-2 dual agonist being developed with ProGen, and on continued validation of the RaniPill platform through partnerships. With roughly $49.7 million in cash at the end of 2025 and a runway management projects into the fourth quarter of 2027, the company has time, but it remains a pre-revenue, loss-making business with no reported EPS (earnings per share) profitability.
RANI sits near its 52-week low of about $0.57, well below its 50-day moving average near $0.78 and 200-day moving average near $0.95. These moving averages now act as overhead resistance zones, and the prior 52-week high near $2.63 is far above any realistic near-term support. With short interest of roughly seven percent of float and more than a dozen days to cover, the stock also carries meaningful technical and positioning risk.
Analyst price targets generally reflect a research horizon of around 12 months, though individual firms vary. The most important upcoming items are the next quarterly earnings report, updates on the RT-114 Phase 1 study, any new collaboration or milestone announcements under the Chugai agreement, and further financing or capital-raising activity. Changes to analyst targets or ratings following clinical data readouts will also be closely watched.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening allows. For investors tracking volatile names like RANI, such tools can help contextualize short-term price action alongside longer-term research.
Reaching $7.20 from roughly $0.61 would require a gain of more than 1,000%, making this an extraordinary objective even though it is derived directly from the average of five analyst targets. The bull case rests on the RaniPill platform's potential to convert injectable biologics into oral therapies, validated by the Chugai collaboration and a growing obesity pipeline. The bear case emphasizes pre-revenue financials, ongoing capital needs, and the substantial risk inherent in early-stage clinical development. With a target range of $5 to $11, analysts agree on direction but not magnitude, and investors should treat the $7.20 figure as a reflection of that wide dispersion rather than a precise forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RANI has been loosely correlated with NCEL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RANI jumps, then NCEL could also see price increases.
| Ticker / NAME | Correlation To RANI | 1D Price Change % | ||
|---|---|---|---|---|
| RANI | 100% | -2.47% | ||
| NCEL - RANI | 46% Loosely correlated | +4.00% | ||
| ARMP - RANI | 44% Loosely correlated | -1.32% | ||
| RXRX - RANI | 41% Loosely correlated | -6.70% | ||
| IMVT - RANI | 40% Loosely correlated | +1.59% | ||
| RCKT - RANI | 40% Loosely correlated | -3.16% | ||
More | ||||